Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Oct 10;16(10):437-44.
doi: 10.1186/2047-783x-16-10-437.

Trimodal therapy in squamous cell carcinoma of the esophagus

Affiliations

Trimodal therapy in squamous cell carcinoma of the esophagus

C Matuschek et al. Eur J Med Res. .

Abstract

Patients with ESCC (squamous cell carcinoma of the esophagus) are most commonly diagnosed with locally advanced tumor stages. Early metastatic disease and late diagnosis are common reasons responsible for this tumor's poor clinical outcome. The prognosis of esophageal cancer is very poor because patients usually do not have symptoms in early disease stages. Squamous cell carcinoma of the esophagus frequently complicates patients with multiple co-morbidities and these patients often require interdisciplinary diagnosis and treatment procedures. At present time, neoadjuvant radiation therapy and chemotherapy followed by surgery are regarded as the international standard of care. Meta-analyses have confirmed that this approach provides the patient with better local tumor control and an increased overall survival rate. It is recommended that patients with positive tumor response to neoadjuvant therapy and who are poor surgical candidates should consider definitive radiochemotherapy without surgery as a treatment option. In future, EGFR antibodies may also be administered to patients during therapy to improve the current treatment effectiveness. Positron-emission tomography proves to be an early response-imaging tool used to evaluate the effect of the neoadjuvant therapy and could be used as a predictive factor for the survival rate in ESCC. The percentage proportions of residual tumor cells in the histopathological analyses represent a gold standard for evaluating the response rate to radiochemotherapy. In the future, early response evaluation and molecular biological tests could be important diagnostic tools in influencing the treatment decisions of ESCC patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
a-c, Treatment plan and dose distribution for 3-D conformal radiation therapy.
Figure 2
Figure 2
PET-CT with a clear circular wall thickening in the middle section of the esophagus and increased glucose uptake (SUV max. 14,2). Prestenotic dilatation and bone metatasis (thoracic vertebrae 3 and 12).

References

    1. Jemal A, Murray T, Ward E. et al.Cancer statistics. Ca Cancer J Clin. 2005;55(1):10–30. doi: 10.3322/canjclin.55.1.10. - DOI - PubMed
    1. Matuschek C, Bölke E, Peiper M, Knoefel WT, Budach W, Erhardt A, Scherer A, Gerber PA, Buhren BA, Gattermann N, Baldus SE, Rusnak E, Shukla V, Orth K. The role of neoadjuvant and adjuvant treatment for adenocarcinoma of the upper gastrointestinal tract. Eur J Med Res. 2011;16(6):265–274. - PMC - PubMed
    1. Siewert JR, Feith M, Stein H. Esophagectomy as therapeutic principle for squamous cell esophageal cancer. Chirurg. 2005;76:1033–1043. doi: 10.1007/s00104-005-1096-9. - DOI - PubMed
    1. Siewert JR, Feith M, Werner M, Stein H. Adenocarcinoma of the esophagogastric junction. Results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg. 2000;232:353–361. doi: 10.1097/00000658-200009000-00007. - DOI - PMC - PubMed
    1. Kelsen DP, Ginsberg R, Pajak TF. et al.Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998;339:1979–1984. doi: 10.1056/NEJM199812313392704. - DOI - PubMed